QyPredict®: an AI prediction technology for optimizing patient selection in clinical trials to be presented at the CTAD Conference by QYNAPSE

QYNAPSE will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The software computes a cognitive decline risk score that can be used to enrich patient selection strategy with the aim to increase clinical trial success probability.

Qynapse sponsors the 8th joint ACTRIMS-ECTRIMS meeting – MSVirtual2020

Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS). The latest QyScore® validation and performance advances will be presented during the conference.

Qynapse is pleased to participate in the 2020 Alzheimer’s Association International Conference virtual event

Qynapse is thrilled to be part of the Scientific Program of AAIC and the Virtual Exhibition from July 27 to July 31 − to present our latest advances and solutions.

Qynapse exhibits at the 2019 Alzheimer’s Association International Conference (AAIC) in Los Angeles, CA

From July 14 – 18th, Qynapse will be part of the 2019 Alzheimer’s Association International Conference® (AAIC®) held in Los Angeles, California

Qynapse attended the 14th AD/PD International Conference

Qynapse took part in the 2019 International Conference on Alzheimer’s & Parkinson’s Disease (AD/PDTM) in Lisbon, Portugal from March 26 – 31st

Qynapse exhibited at 2018 Alzheimer’s conference AAIC in Chicago

From July 22– 26th, Qynapse took part in the 2018 Alzheimer’s Association International Conference® (AAIC®) held in Chicago, Illinois